 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| Apixaban for Secondary Stroke Prevention: Coexistant Cerebral Atherosclerosis May Increase Recurrent Strokes |
| Jong S. Kim, Jaseong Koo, Dong-Ick Shin, Byung-Su Kim, Jei Kim, Eung-Gyu Kim, Keun-Sik Hong, Hyeju Yi |
|
J Stroke. 2022;24(1):118-127. Published online January 31, 2022 DOI: https://doi.org/10.5853/jos.2021.02355 |
|
Apixaban for Secondary Stroke Prevention: Coexistant Cerebral Atherosclerosis May Increase Recurrent Strokes Journal of Stroke. 2022;24(1):118-127  Cilostazol in secondary prevention of stroke: Impact of the Cilostazol Stroke Prevention Study Atherosclerosis Supplements. 2005;6(4):33-40 Effect of Postural Hypotension on Recurrent Stroke: Secondary Prevention of Small Subcortical Strokes (SPS3) Study Journal of Stroke and Cerebrovascular Diseases. 2019;28(8):2124-2131 Review: Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes? Therapeutic Advances in Cardiovascular Disease. 2008;2(5):387-405 Secondary Prevention after Ischemic Strokes due to Hypercoagulable States Ischemic Stroke Therapeutics. 2016;189-194 Dyslipidemia as a risk factor of cerebral atherosclerosis and the target for secondary prevention Atherosclerosis. 1999;144:180 Secondary prevention of small subcortical strokes (SPS3) Seminars in Cerebrovascular Diseases and Stroke. 2003;3(1):8-17 STUDY ON LIPIDS IN CEREBRAL ATHEROSCLEROTIC ISCHEMIC STROKES Atherosclerosis Supplements. 2008;9(1):248 Cerebral venous thrombosis Treatment-Related Stroke. 2016;241-254 Secondary Prevention After Non-atherosclerotic Cerebral Vasculopathies Ischemic Stroke Therapeutics. 2016;169-187 |
